• Two phase 2 trials including hundreds of participants with type 2 diabetes from several countries assessed the safety and efficacy of a long-acting form of insulin called “insulin icodec.”
• One trial found that using injectable insulin icodec once a week was as effective as using a standard injectable form of insulin once a day.
• The other trial found that it seems to be safe and effective to transition from a standard daily insulin injectable to weekly icodec injections.
• If these findings are confirmed by further research, they could help greatly reduce the burden and barriers associated with more frequent insulin injections.

Written by Jennifer Huizen on April 25, 2021

Fact checked by Rita Ponce, Ph.D.

Read full Article